Abstract
The disease burden of leishmaniases is widely studied and is an important instrument to plan a strategy to control or prevent this disease. One featured scenario is the lack of innovation in drug discovery toward novel anti-parasitic agents to control and treat leishmaniases. This is an important concern, and the genome sequencing of several Leishmania species is able to accelerate the id…
